(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 March 2012 (22.03.2012)

PCT

(10) International Publication Number
WO 2012/037534 A1

(51) International Patent Classification:
A61K 38/00 (2006.01) *A61K 47/18* (2006.01)
A61K 38/48 (2006.01) *A61K 9/00* (2006.01)
A61K 39/395 (2006.01) *A61K 47/12* (2006.01)
A61K 47/02 (2006.01)

(21) International Application Number:
PCT/US2011/052053

(22) International Filing Date:
16 September 2011 (16.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/384,209 17 September 2010 (17.09.2010) US

(71) Applicants *(for all designated States except US)*: **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deefield, IL 60015 (US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauerstrasse 130, 8152 Glattpark (Opfikon) (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BUTTERWECK, Harald, Arno** [AT/AT]; Naufahrtweg 5, A-1220 Wien (AT). **KÖLBL, Bernhard** [AT/AT]; Hintausstrasse 20/5, 2481 Achau (AT). **HOFBAUER, Lucia** [AT/AT]; Grafenbert 9, A-3730 Eggenburg (AT). **TESCHNER, Wolfgang** [DE/AT]; Gestettengasse 19/14, A-1030 Wien (AT). **SCHWARZ, Hans-Peter** [AT/AT]; Weimarer Strasse 76, A-1180 Wien (AT).

(74) Agent: **PARENT, Annette, S.**; Morgan, Lewis & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH




FIG. 1

(57) Abstract: The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration.

WO 2012/037534 A1